<https://rdf.molmedb.upol.cz/reference/ref3526> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490999>,
		<https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.6b00519"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21>,
		<https://identifiers.org/molmedb/MM489036>;
	<http://purl.org/ontology/bibo/pmid> "27259031"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Degorce SL, Barlaam B, Cadogan E, Dishington A, Ducray R, Glossop SC, Hassall LA, Lach F, Lau A, McGuire TM, Nowak T, Ouvry G, Pike KG, Thomason AG.: Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. J Med Chem, Volume 59 (13), 2016"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1024874> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3526> .
<https://rdf.molmedb.upol.cz/interaction/int1024735> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3526> .